A new era in the treatment of primary pulmonary hypertension.
Bailey
C L
CL
Channick
R N
RN
Rubin
L J
LJ
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D011464:Epoprostenol / Q000627:therapeutic use*; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D009569:Nitric Oxide / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013931:Thromboxanes / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000959:Antihypertensive Agents; D013449:Sulfonamides; D013931:Thromboxanes; D014665:Vasodilator Agents; D009569:Nitric Oxide; D011464:Epoprostenol; D000077300:Bosentan